An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.

"The dosage of amivantamab will be based on the participant's body weight during screening. Participants will receive 1,050 mg if BW is \<80 kg or 1,400 mg if BW is ≥80 kg.~* Cycle 1: once weekly (with the first dose split over Day -2 \[350 mg, IVF for 4-6hrs\] and Day -1 \[remainder of the dose, IVF for 6-8hrs\]; subsequent dose \[planned dose IVF over 2 hrs\]).~* Cycles 2+: Days 1 and 15 of each cycle (planned dose IVF over 2 hrs) On days when both amivantamab and chemotherapy are administered, amivantamab should be administered before chemotherapy. In general, leucovorin 400 mg/m2 IV over 2 hours and irinotecan 180 mg/m2 IV over 90 min, then 5-FU 400 mg/m2 IV bolus followed by 5-FU continuous infusion 2,400 mg/m2 over approximately 46-48 hours or 1,200 mg/m2/day for two days. Irinotecan and leucovorin may be administered concurrently (via separate infusion lines) or sequentially according to the institutional standard."